BRIEF published on 11/07/2025 at 15:44, 27 days 19 hours ago Virbac: Update on shares and voting rights Euronext Paris Voting Rights Actions Transparency VIRBAC
BRIEF published on 09/12/2025 at 17:50, 2 months 22 days ago Virbac Reports Solid Growth in 2025 First Half Results Revenue Growth Operating Income VIRBAC 2025 Forecast Global Market Performance
PRESS RELEASE published on 09/12/2025 at 17:45, 2 months 22 days ago Virbac: 2025 Half-year results Virbac reports solid revenue growth of 5.6% in the first half of 2025, meeting adjusted operating income expectations. Targets for 2025 confirmed with revenue growth of 4-6% expected Financial Results Revenue Growth Operating Income VIRBAC Targets Confirmed
BRIEF published on 08/18/2025 at 09:35, 3 months 18 days ago Virbac reveals the remuneration of its new CEO General Manager Remuneration VIRBAC Free Shares Paul Martingell
PRESS RELEASE published on 08/18/2025 at 09:30, 3 months 18 days ago Virbac:: Paul Martingell's compensation terms Virbac's board of directors approves compensation terms for Paul Martingell as CEO, including fixed and variable components, long-term incentives, and exceptional benefits Board Of Directors CEO VIRBAC Paul Martingell Compensation Terms
BRIEF published on 07/04/2025 at 12:09, 5 months ago Virbac: Status of Shares and Voting Rights as of June 30, 2025 Euronext Paris Voting Rights Actions 2025 VIRBAC
PRESS RELEASE published on 07/04/2025 at 12:04, 5 months ago Virbac : Declaration of the number of shares and voting rights 06/2025 Declaration of the number of shares and voting rights for VIRBAC on Euronext Paris. Total voting rights: 12,706,453. Net total voting rights: 12,693,617 Euronext Paris Voting Rights Shares Financial Market Authority VIRBAC
BRIEF published on 06/19/2025 at 08:35, 5 months 16 days ago Virbac appoints Paul Martingell as CEO from September 2025 Appointment Animal Health Leadership VIRBAC Paul Martingell
PRESS RELEASE published on 06/19/2025 at 08:30, 5 months 16 days ago VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effective September 1, 2025 Paul Martingell appointed CEO of Virbac, effective Sept 1, 2025. Recognized leader with extensive international experience in consumer health, consumer goods, and pharmaceuticals Pharmaceuticals CEO VIRBAC Consumer Health Paul Martingell
BRIEF published on 06/10/2025 at 10:04, 5 months 25 days ago Virbac Announces Share and Voting Rights for May 2025 Euronext Paris Voting Rights Shares Financial Declaration VIRBAC
Published on 12/05/2025 at 02:35, 8 hours 46 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 10 hours 21 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 16 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 21 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 10:30, 51 minutes ago Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 6 minutes ago Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 40 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 1 hour 51 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 08:45, 2 hours 36 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 17 hours 21 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 17 hours 36 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 17 hours 37 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 4 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
